Imagine trying to find a key for a lock, but the lock is invisible and changes shape. Current computers guess the shape, but often get it wrong, leading to expensive failures in the lab. This software uses quantum physics to create a perfect digital map of the lock, so scientists know exactly which key works before they ever touch a test tube.
Drug discovery is currently too slow and expensive, with success rates as low as 10-12% and costs reaching €2.5bn per drug. This is largely due to inaccurate molecular simulations that lead to failures in the wet-lab stage.
Kvaser, a hardware-agnostic software platform that combines quantum computing and high-performance computing, featuring a novel unbinding-kinetics algorithm for ligand ranking.
If you are a pharmaceutical giant dealing with a 10-15 year timeline for a successful drug, this project developed a quantum-agnostic platform that provides faster, accurate ranking of ligands. This reduces the reliance on wet-lab experiments and helps lower the €2.5bn average cost of drug development.
If you are a biotech firm dealing with inaccurate simulations of biochemical systems, this project developed Kvaser, a user-friendly tool that combines quantum and high-performance computing. It allows non-coding experts to run high-precision calculations to identify viable drug candidates faster.
If you are a Computer-Aided Drug Design provider dealing with slow simulation routines, this project developed an unbinding-kinetics algorithm. This provides a way to offer customers unmatched speed and accuracy in molecular simulations regardless of the quantum hardware used.
By providing more accurate simulations and ligand ranking, the platform aims to reduce the number of failed trials and the need for expensive wet-lab and animal testing. This targets the 42-50% of development costs currently spent on discovery and preclinical stages.
Yes, the project specifically developed a quantum-hardware-agnostic software tool, meaning it is designed to work across different types of quantum hardware.
The platform is designed for the chemistry and pharma industry to handle complex computational problems that are currently beyond the scope of the world's largest supercomputers.
Based on available project data, the specific licensing terms are not disclosed, but the project focuses on developing a proprietary software platform called Kvaser.
The project period runs from 2023-08-01 to 2025-07-31, aiming to move quantum computing closer to commercial utility for pharma R&D.
The project is led by a single SME, Kvantify APS from Denmark, which holds 100% of the industry ratio. This lean structure suggests a highly focused development cycle where the coordinator maintains full control over the intellectual property and the software's direction.
Contact KVANTIFY APS in Denmark regarding the Kvaser platform
Contact us to explore licensing or partnership opportunities with Kvantify APS.
